Pharmacological inhibition of AXL using BGB324 has demonstrated efficacy in overcoming both TKI-sensitive and TKI-resistant CML cells, including those harboring the T315I mutation, which is resistant to most TKIs except ponatinib [248]. This evidence concerns the gene AXL and chronic myelogenous leukemia, BCR-ABL1 positive.